Mexico: A closer look at post-filing data in patent applications

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Mexico: A closer look at post-filing data in patent applications

Sponsored by

olivares-400px.jpg
specs-6500153-1280.jpg

Rommy Morales of OLIVARES explains the key elements to consider for submitting post-filing experimental evidence

Mexican patent law does not require experimental evidence covering every embodiment within the scope of a claim. However, it provides that that the description of the invention has to disclose the invention in a sufficiently clear and complete way to allow a person skilled in the art to make it, and the best method known to the applicant of carrying out the invention, as well as the information to support the industrial application of the invention. 

Therefore, even though the claims should be considered as commensurate in scope with a reasonable generalisation of the disclosed examples, in practice, when an application does not include experimental evidence for all the embodiments, examiners sometimes raise sufficiency of disclosure, clarity, support and/or inventive step objections.

When the above-mentioned objections are raised, examiners commonly object that the disclosure in the specification is not sufficiently complete and/or it does not contain the best-known method to perform the invention. Examiners also state that the inventive step cannot be recognised due to the experimental evidence provided in the application that does not demonstrate the technical effect.

Even though Mexican law provides that the Mexican Institute of Industrial Property (IMPI) may require the submission of additional or complementary information or documentation, it does not include any specific provision about post-filing submission of experimental data. Under the local practice, post-filing experimental evidence is normally accepted as long as the said evidence is filed along with the response to the substantive office action wherein the said objections were raised, and when the alleged technical effect is expressly disclosed in or can be inferred or derivable from the originally filed application. 

Finally, it is important to bear in mind that there is no precedent case law, such as jurisprudence, regulations or guidelines about this issue in Mexico, and thus the acceptance thereof would depend on the examiner overseeing examination of the application.

 

Rommy Morales

Biologist, OLIVARES

E: rommy.morales@olivares.mx

 

more from across site and SHARED ros bottom lb

More from across our site

Junior lawyers aren’t unwilling to work hard, as some seniors believe; rather, they are rejecting traditional career advancement models that have limited payoff
Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Gift this article